GraniteShares 1.5x Long Coinbase Daily ETF

Direxion Daily S&P Biotech Bull 3X ETF

iPath S&P 500 VIX ST Futures ETN

GraniteShares 1.5x Short NVDA Daily ETF

ARK Innovation ETF

Direxion Daily Small Cap Bull 3X ETF

ProShares UltraPro Dow30

ProShares UltraPro Short QQQ

ProShares UltraShort Silver

Health Care Select Sector SPDR ETF

Altimmune Inc. Common Stock

ProShares Ultra Semiconductors

GraniteShares 1.5x Long META Daily ETF

Direxion Daily S&P Biotech Bear 3X ETF

Mast Therapeutics, Inc.

GraniteShares 1.5x Long NVDA Daily ETF

Direxion Daily FTSE China Bull 3X ETF

GraniteShares 2x Long AMZN Daily ETF

Global X Uranium ETF

ProShares UltraPro QQQ

Siyata Mobile Inc. Common Shares

Capstone Holding Corp. Common Stock

Amesite Inc. Common Stock

Virgin Galactic Holdings Inc. Common Stock

Classover Holdings Inc. Class B Common Stock

Pasithea Therapeutics Corp. Common Stock

Gryphon Digital Mining Inc Common Stock

CoreWeave Inc. Class A Common Stock

Luminar Technologies Inc.  Class A Common Stock

Applied Digital Corporation Common Stock

Click Holdings Limited Ordinary Share

US Foods Holding Corp. Common Stock

Crown LNG Holdings Limited Ordinary Shares

Incannex Healthcare Limited American Depositary Shares

Aytu BioPharma Inc.  Common Stock

Nuvve Holding Corp. Common Stock

Asset Entities Inc. Class B Common Stock

Next Technology Holding Inc. Ordinary Shares

MicroAlgo Inc. Ordinary Shares

Hyperscale Data Inc. Common Stock

Click here to get full coverage on Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire

Scilex Holding Company Announces 1-for-35 Reverse Stock Split  GlobeNewswire

Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire

Click here to get full coverage on Scilex (SCLX) Shares Findings from CLEAR Trial at Pain Conferenc - GuruFocus

Scilex (SCLX) Shares Findings from CLEAR Trial at Pain Conferenc  GuruFocus

Scilex (SCLX) Shares Findings from CLEAR Trial at Pain Conferenc - GuruFocus

Click here to get full coverage on Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st

Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny  simplywall.st

Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st

Click here to get full coverage on D. Boral Capital Initiates Coverage of Scilex Holding (SCLX) with Buy Recommendation - Nasdaq

D. Boral Capital Initiates Coverage of Scilex Holding (SCLX) with Buy Recommendation  Nasdaq

D. Boral Capital Initiates Coverage of Scilex Holding (SCLX) with Buy Recommendation - Nasdaq

Click here to get full coverage on What Does the Market Think About Scilex Holding? - Scilex Holding (NASDAQ:SCLX) - Benzinga

What Does the Market Think About Scilex Holding? - Scilex Holding (NASDAQ:SCLX)  Benzinga

What Does the Market Think About Scilex Holding? - Scilex Holding (NASDAQ:SCLX) - Benzinga

Click here to get full coverage on SCLX stock touches 52-week low at $5.8 amid market challenges - Investing.com

SCLX stock touches 52-week low at $5.8 amid market challenges  Investing.com

SCLX stock touches 52-week low at $5.8 amid market challenges - Investing.com

Click here to get full coverage on Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - Yahoo Finance

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional  Yahoo Finance

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - Yahoo Finance

Click here to get full coverage on Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks

Scilex Adjusts Record Date for Preferred Stock Dividend  TipRanks

Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks

Click here to get full coverage on Scilex Holding Full Year 2024 Earnings: EPS Beats Expectations - simplywall.st

Scilex Holding Full Year 2024 Earnings: EPS Beats Expectations  simplywall.st

Scilex Holding Full Year 2024 Earnings: EPS Beats Expectations - simplywall.st

Click here to get full coverage on Scilex Announces 1-for-35 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq

Scilex Announces 1-for-35 Reverse Stock Split To Regain Nasdaq Compliance  Nasdaq

Scilex Announces 1-for-35 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq

Click here to get full coverage on Scilex Holding Company Announces Change in Record Date for - GlobeNewswire

Scilex Holding Company Announces Change in Record Date for  GlobeNewswire

Scilex Holding Company Announces Change in Record Date for - GlobeNewswire

Click here to get full coverage on Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - simplywall.st

Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m  simplywall.st

Private companies who have a significant stake must be disappointed along with institutions after Scilex Holding Company's (NASDAQ:SCLX) market cap dropped by US$22m - simplywall.st

Click here to get full coverage on Scilex Holding Company Announces that the U.S. Bankruptcy - GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy  GlobeNewswire

Scilex Holding Company Announces that the U.S. Bankruptcy - GlobeNewswire

Click here to get full coverage on Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - GlobeNewswire

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva  GlobeNewswire

Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - GlobeNewswire

Click here to get full coverage on Scilex Holding Company sets November 7, 2024 as the Record - GlobeNewswire

Scilex Holding Company sets November 7, 2024 as the Record  GlobeNewswire

Scilex Holding Company sets November 7, 2024 as the Record - GlobeNewswire

Click here to get full coverage on Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire

Scilex Holding Company Announces FDA Has Approved Our  GlobeNewswire

Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire

Click here to get full coverage on SCLX stock touches 52-week low at $0.38 amid market challenges - Investing.com

SCLX stock touches 52-week low at $0.38 amid market challenges  Investing.com

SCLX stock touches 52-week low at $0.38 amid market challenges - Investing.com

Click here to get full coverage on Scilex Updates Director Compensation Following Stock Split - TipRanks

Scilex Updates Director Compensation Following Stock Split  TipRanks

Scilex Updates Director Compensation Following Stock Split - TipRanks

Click here to get full coverage on Scilex adjusts director compensation post-stock split - Investing.com

Scilex adjusts director compensation post-stock split  Investing.com

Scilex adjusts director compensation post-stock split - Investing.com

Click here to get full coverage on Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PR Newswire

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt  PR Newswire

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PR Newswire

Click here to get full coverage on Scilex Holding Company Announces $17 Million Registered Direct Offering - GlobeNewswire

Scilex Holding Company Announces $17 Million Registered Direct Offering  GlobeNewswire

Scilex Holding Company Announces $17 Million Registered Direct Offering - GlobeNewswire

Click here to get full coverage on Scilex Holding Company, Following its Prior Announcement of - GlobeNewswire

Scilex Holding Company, Following its Prior Announcement of  GlobeNewswire

Scilex Holding Company, Following its Prior Announcement of - GlobeNewswire

Click here to get full coverage on Scilex shares face delisting risk on Nasdaq - Investing.com

Scilex shares face delisting risk on Nasdaq  Investing.com

Scilex shares face delisting risk on Nasdaq - Investing.com

Click here to get full coverage on Scilex downgraded to Hold from Buy at D. Boral Capital - Yahoo Finance

Scilex downgraded to Hold from Buy at D. Boral Capital  Yahoo Finance

Scilex downgraded to Hold from Buy at D. Boral Capital - Yahoo Finance

Click here to get full coverage on NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire

NeuroBiogen Company and Scilex Bio, a Controlling Interest  GlobeNewswire

NeuroBiogen Company and Scilex Bio, a Controlling Interest - GlobeNewswire

Click here to get full coverage on Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules - Investing.com Nigeria

Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules  Investing.com Nigeria

Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules - Investing.com Nigeria

Click here to get full coverage on Scilex Holding Company Announces Change to Record Date for Preferred Stock Dividend - Nasdaq

Scilex Holding Company Announces Change to Record Date for Preferred Stock Dividend  Nasdaq

Scilex Holding Company Announces Change to Record Date for Preferred Stock Dividend - Nasdaq

Click here to get full coverage on Scilex Announces New Record Date for Preferred Stock - TipRanks

Scilex Announces New Record Date for Preferred Stock  TipRanks

Scilex Announces New Record Date for Preferred Stock - TipRanks

Click here to get full coverage on Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of - GlobeNewswire

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of  GlobeNewswire

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of - GlobeNewswire

Click here to get full coverage on Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire

Scilex Holding Company Announces Signing of a $50 Million  GlobeNewswire

Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire

Click here to get full coverage on Scilex Holding announces 1-for-35 reverse stock split - Investing.com

Scilex Holding announces 1-for-35 reverse stock split  Investing.com

Scilex Holding announces 1-for-35 reverse stock split - Investing.com

Click here to get full coverage on Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - GlobeNewswire

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025  GlobeNewswire

Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025 - GlobeNewswire

Click here to get full coverage on Scilex Holding ends sales agreement, shares details - Investing.com

Scilex Holding ends sales agreement, shares details  Investing.com

Scilex Holding ends sales agreement, shares details - Investing.com

Click here to get full coverage on FDA grants orphan status to Scilex’s pericarditis drug - Investing.com

FDA grants orphan status to Scilex’s pericarditis drug  Investing.com

FDA grants orphan status to Scilex’s pericarditis drug - Investing.com

Click here to get full coverage on Scilex stock rating downgraded at Boral Capital - Investing.com

Scilex stock rating downgraded at Boral Capital  Investing.com

Scilex stock rating downgraded at Boral Capital - Investing.com

Click here to get full coverage on Scilex Holding Company Announces that It Will Be Filing - GlobeNewswire

Scilex Holding Company Announces that It Will Be Filing  GlobeNewswire

Scilex Holding Company Announces that It Will Be Filing - GlobeNewswire

Click here to get full coverage on Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - GlobeNewswire

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults  GlobeNewswire

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults - GlobeNewswire

Click here to get full coverage on Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - The Manila Times

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional  The Manila Times

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - The Manila Times

Click here to get full coverage on Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - GlobeNewswire

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and  GlobeNewswire

Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and - GlobeNewswire

Click here to get full coverage on Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securit - Yahoo Finance

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securit  Yahoo Finance

Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securit - Yahoo Finance

Click here to get full coverage on Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, - GlobeNewswire

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate,  GlobeNewswire

Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, - GlobeNewswire

Click here to get full coverage on Denali Capital secures extension with Scilex funding - Investing.com

Denali Capital secures extension with Scilex funding  Investing.com

Denali Capital secures extension with Scilex funding - Investing.com

Click here to get full coverage on Scilex Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks

Scilex Announces Reverse Stock Split to Meet Nasdaq Rules  TipRanks

Scilex Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks

Click here to get full coverage on Canada approves Scilex’s migraine solution ELYXYB - Investing.com

Canada approves Scilex’s migraine solution ELYXYB  Investing.com

Canada approves Scilex’s migraine solution ELYXYB - Investing.com

Click here to get full coverage on Scilex adjusts director compensation post-stock split By Investing.com - Investing.com India

Scilex adjusts director compensation post-stock split By Investing.com  Investing.com India

Scilex adjusts director compensation post-stock split By Investing.com - Investing.com India

Click here to get full coverage on Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - GlobeNewswire

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC  GlobeNewswire

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - GlobeNewswire

Click here to get full coverage on Scilex to Implement 1-for-35 Reverse Stock Split - marketscreener.com

Scilex to Implement 1-for-35 Reverse Stock Split  marketscreener.com

Scilex to Implement 1-for-35 Reverse Stock Split - marketscreener.com

Click here to get full coverage on Scilex Holding Company Announces that the U.S. FDA Has - GlobeNewswire

Scilex Holding Company Announces that the U.S. FDA Has  GlobeNewswire

Scilex Holding Company Announces that the U.S. FDA Has - GlobeNewswire

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com India

Scilex Holding Amends Merger Agreement with Denali By Investing.com  Investing.com India

Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com India

Click here to get full coverage on Scilex Holding Company Announces 5-Year Term of $100 - GlobeNewswire

Scilex Holding Company Announces 5-Year Term of $100  GlobeNewswire

Scilex Holding Company Announces 5-Year Term of $100 - GlobeNewswire

Click here to get full coverage on Palo Alto pharmaceutical company secures $17M - The Business Journals

Palo Alto pharmaceutical company secures $17M  The Business Journals

Palo Alto pharmaceutical company secures $17M - The Business Journals

Click here to get full coverage on Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal - Reuters

Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal  Reuters

Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal - Reuters

Click here to get full coverage on Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 - Seeking Alpha

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024  Seeking Alpha

Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 - Seeking Alpha

Scilex Holding Company (SCLX)

Price Chart

Key Statistics

Technicals

About SCLX

Latest News

Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire

Scilex (SCLX) Shares Findings from CLEAR Trial at Pain Conferenc - GuruFocus

Scilex Holding Company (NASDAQ:SCLX) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st

Advanced Charts

Top Gainers

Top Losers